Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
Status:
Not yet recruiting
Trial end date:
2033-01-25
Target enrollment:
Participant gender:
Summary
This study is being done to examine the safety and effectiveness of pirtobrutinib combined
with venetoclax as a possible treatment for participants with Waldenström Macroglobulinemia
(WM).
The names of the study drugs involved in this study are:
- Pirtobrutinib (a Noncovalent Bruton Tyrosine Kinase (BTK) inhibitor)
- Venetoclax (a BCL2 inhibitor)